Summary of Key Points:
China Biopharmaceutical has licensed its domestically developed innovative drug for chronic obstructive pulmonary disease (COPD), TQC3721, to the global respiratory giant AstraZeneca, for a fee of up to $1.9 billion. This transaction sets a new record for the highest amount licensed for a single product in the domestic respiratory sector in nearly three years. TQC3721 is a PDE3/4 inhibitor, representing the first innovative inhalation therapy for COPD in over 20 years and holds significant market potential. AstraZeneca's acquisition strengthens its position in the respiratory field, while licensing has become an important source of revenue for Chinese pharmaceutical companies, with a surge in overseas transactions in the first half of this year.
Detailed Analysis:
Why is the $1.9 billion deal considered the "largest in the respiratory sector"?**
There are two main reasons behind this record-breaking transaction:
1. The urgent need for treatment: COPD is the third leading cause of death worldwide and is more lethal than many diseases, including cancer and heart disease. Although existing treatments (such as inhaled corticosteroids and long-acting bronchodilators) have been used for years, many patients still experience sudden exacerbations and weakened immune systems, making new therapies essential.
2. The competitiveness of the PDE3/4 inhibitor category: As the first innovative inhalation drug in COPD in over 20 years, this class is considered to have a global market worth billions of dollars. Merck spent $10 billion last year to acquire a company developing such drugs, highlighting the industry's enthusiasm. AstraZeneca's investment reflects its belief that TQC3721 can address unmet patient needs and capture this large market.
Comparing with previous deals, Hengrui Medicine licensed its PDE3/4 drug to GSK last year, and Hisco licensed it to AirNexis this year, both for amounts below $1.9 billion, making this the highest deal in the respiratory sector in recent years.
What makes TQC3721 so attractive?
There are several key features that have impressed AstraZeneca:
- Dual dosage forms for all patients: The drug is available as an aerosol (suitable for elderly, children, and patients with severe breathing difficulties) and a dry powder (convenient for younger patients), covering a wide range of users and scenarios.
- Complementary to existing treatments: It can be used in combination with other bronchodilators, improving lung function and reducing acute exacerbations, thus addressing the limitations of current therapies.
- Broad applications and potential: TQC3721 can treat not only COPD but also asthma and pulmonary fibrosis, expanding its market potential. Clinical trials for the aerosol formulation are in Phase III (just one step away from market launch), while the dry powder formulation is in Phase II, indicating relatively low risk.
Is AstraZeneca's investment a strategic necessity?
As the global leader in respiratory medicine with annual revenue exceeding $1.5 billion from respiratory and immunology products, AstraZeneca needs to continuously innovate to maintain its position. TQC3721 fills an important gap in its portfolio by addressing unmet patient needs and enhancing its product lineup. This acquisition is crucial for AstraZeneca to strengthen its leading role in the industry.
Accelerating trend of Chinese innovative drugs entering international markets:
This deal is not an isolated case; it reflects a broader trend of Chinese pharmaceutical companies expanding their presence overseas:
- Company-level: China Biopharmaceutical has made four licensing agreements, with initial payments totaling over $1 billion and total transaction values exceeding $7 billion. Licensing allows companies to generate immediate revenue without building their own international sales teams and to leverage giants' distribution networks.
- Industry-level: According to MedTech Magic Cube data, the total value of Chinese pharmaceutical licensing transactions in the first half of 2026 reached $99.7 billion, doubling that of 2024 and accounting for nearly 73% of 2025's annual total. This indicates growing recognition of Chinese innovation by international companies, with licensing becoming a key pathway for revenue generation and development.
In summary, this transaction is a victory for China Biopharmaceutical and demonstrates the progress of Chinese pharmaceutical innovation. It also shows that Chinese companies are moving from following to leading in the global market, with an accelerating pace of overseas expansion.